Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Rectal Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Congenital Abnormalities 2Colorectal Neoplasms 2Colonic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
73 enrolled 16 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Completed
47 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡